Top 5 Casino Stocks To Invest In 2017

Top 5 Casino Stocks To Invest In 2017: Dermira, Inc.(DERM)

Advisors' Opinion:

• [By Ben Levisohn]

  Current market dynamics, particularly in the SMID biotech universe, provide a plethora of opportunities for the company to augment the breadth and depth its pipeline in its core therapeutic areas, including neurology, ophthalmology and dermatology, where innovation is rife and where consolidation of some of the smaller players in the space is likely, in our view. Stocks in our SMID coverage universe that could potentially constitute future acquisition targets forAllergan include Aclaris Therapeutics (ACRS) and Dermira (DERM) (both have mid- to late-stage dermatology assets in development). We note with interest the collaboration with Heptares announced yesterday evening for the development of several M1, M4 and dual M1/M4 agonists in development for a variety of neurological diseases, including Alzheimers disease. Notwithstanding this above, larger scale transactions of course cannot be ruled out, and we note todays market commentary (Fox Business) regarding the po tential sale of Valeant Pharmaceuticals International’s (VRX) Bausch & Lomb unit. It is reasonable to assume thatAllergan could be a bidder for this asset, given the companys presence in ophthalmology, as well as CEO Brent Saunders familiarity with the asset (he was the CEO prior to its sale toValeant in 2013 for $8.7bn). At the time of its sale to Valeant, B&L was generating c.$3bn in revenues and growing at a double-digit rate. Current sales of the asset are unclear due to the reporting structure of Valeant, as well as concerns regarding the companys operating/ pricing strategy.

source from Top Stocks For 2015:http://www.topstocksblog.com/top-5-casino-stocks-to-invest-in-2017.html